Analytical Data
-
Gene name
SP-B
- Application
-
Alternative Names
SP-B；SAP49；Splicing factor 3B subunit 4
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q15427
-
Expression Region
2-424aa
-
AA Sequence
AAGPISERN QDATVYVGGL DEKVSEPLLW ELFLQAGPVV NTHMPKDRVT GQHQGYGFVE FLSEEDADYA IKIMNMIKLY GKPIRVNKAS AHNKNLDVGA NIFIGNLDPE IDEKLLYDTF SAFGVILQTP KIMRDPDTGN SKGYAFINFA SFDASDAAIE AMNGQYLCNR PITVSYAFKK DSKGERHGSA AERLLAAQNP LSQADRPHQL FADAPPPPSA PNPVVSSLGS GLPPPGMPPP GSFPPPVPPP GALPPGIPPA MPPPPMPPGA AGHGPPSAGT PGAGHPGHGH SHPHPFPPGG MPHPGMSQMQ LAHHGPHGLG HPHAGPPGSG GQPPPRPPPG MPHPGPPPMG MPPRGPPFGS PMGHPGPMPP HGMRGPPPLM PPHGYTGPPR PPPYGYQRGP LPPPRPTPRP PVPPRGPLRG PLPQ
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Surfactant Protein B (SP-B) is a crucial component of pulmonary surfactant, a substance that reduces surface tension in the alveoli, thereby preventing collapse and facilitating gas exchange. Research on SP-B is vital due to its significant role in neonatal respiratory distress syndrome (NRDS) and other pulmonary disorders. SP-B is synthesized in the lungs and plays a pivotal role in the proper functioning of surfactant, which is essential for normal respiratory physiology. Abnormalities in SP-B expression or function can lead to severe lung diseases, highlighting the need for a comprehensive understanding of its structure and function. Recombinant SP-B research has emerged as a promising avenue for therapeutic development, particularly in addressing surfactant deficiencies. Studies have focused on the cloning and expression of SP-B in various systems, enabling detailed analyses of its biochemical properties and mechanisms of action. Moreover, the potential of using SP-B as a target for drug development and novel therapeutic strategies to improve lung function and treat respiratory diseases has gained traction. This research aims to unravel the complexities of SP-B and its implications in respiratory health, contributing to novel diagnostic and therapeutic approaches for lung-related conditions, particularly in vulnerable populations such as premature infants. Ultimately, advancing our knowledge of SP-B and its recombinant forms holds promise for improving clinical outcomes in patients with compromised lung function.
